The Swedish BioFINDER Study

The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.

BioFINDER
One

The first BioFINDER study, launched in 2008, focusing on the early stages of Alzheimer’s and Parkinson’s diseases and related disorders. It includes longitudinal assessments over a period of 6-10 years.

BioFINDER
Two

The second BioFINDER study, launched in 2017, is more comprehensive than BioFINDER One. It includes a larger number of study participants and cutting-edge brain imaging such as tau-PET in all study partcipants.

BioFINDER
Sleep

The BioFINDER Sleep study targeting prodromal Parkinson’s disease was initiated in 2021. It encompasses individuals with REM-sleep behavior disorder and those in the early stages of Parkinson’s disease.

BioFINDER
Preclinical AD

The study, launched in 2022, screens a general population with a blood test to detect preclinical (pre-symptomatic) Alzheimer’s disease. Its goals are to deepen our understanding of the initial stages of the disease and to optimize future primary and secondary prevention trials.

BioFINDER
Primary Care

This BioFINDER study was launched in 2020. It includes diverse patient populations with cognitive symptoms at different primary care centers. The main aim is to improve the diagnostic and prognostic work-up in primary care of neurocognitive disorders using blood biomarkers and brief cognitive tests.

BioFINDER
Memory Clinic

This BioFINDER study, launched in 2023, is complementary to the BioFINDER Primary Care study, but targets a Memory clinic population in a secondary care setting.

News articles

  • Blood Tests: Not Just for the Impaired?

    In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease...

    Read more...

  • Looking Good: Immunoassays for Blood Markers

    For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical...

    Read more...
More news...

X posts

BioFINDER Follow 685 1,478

biofinder_study
biofinder_study avatar BioFINDER @biofinder_study ·
6 Aug 1953015057287180693

🚨New paper alert! This study led by @SEMastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! 🔗 Full article: https://www.nature.com/articles/s41467-025-62458-7.epdf?sharing_token=fJsM7nw6WLFQSLEmJtlXiNRgN0jAjWel9jnR3ZoTv0MDVkWnZxGsgtCMfY18v2PG-JBJvKhRsSwlFHbyWcVEhi_UdJDYtyqFZKb0-1LE-RJuxLzTxso4Wsn_ZLSgyRQKvtbjLPDfKEVHUrWMYnYD648e1kcTBiQcj_tBKohdF6g%3D
A thread🧵👇

biofinder_study avatar BioFINDER @biofinder_study ·
6 Aug 1953015069513576599

6/🧵Taken together, we present an accurate two-step approach for predicting LBP in the brain using a smell test followed by CSF SAA testing in smell-test positive individuals. This could minimize costs, reduce patient burden, and improve the known underdiagnosis of DLB and PD.

biofinder_study avatar BioFINDER @biofinder_study ·
6 Aug 1953015071723954267

A huge thanks to all authors and collaborators who made this work possible! @OskarHansson9 @LECollij @_JakeVogel_ @SebastianPalmqv @FBarkhof @RikOssenkoppele and all not on X.

biofinder_study avatar BioFINDER @biofinder_study ·
5 Aug 1952733774736687180

🚨Publication alert: This study led by @WuestefeldAnika aims to provide a more granular understanding of how tau pathology leads to specific cognitive decline in Alzheimer's disease. 🧠 Out now in Alzheimer’s & Dementia! Read it here:
🧵👇

Image for twitter card

Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease

INTRODUCTION A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's diseas...

doi.org
biofinder_study avatar BioFINDER @biofinder_study ·
5 Aug 1952734039279911009

7⃣This suggests that region-specific atrophy functions as one pathway of tau-induced cognitive subdomain impairments. Yet, large portions of variance remains unexplained, highlighting the need for investigating other mechanistic links.🔬

biofinder_study avatar BioFINDER @biofinder_study ·
5 Aug 1952734166497337715

8⃣A huge thank you to all authors as well as the #ADNI study participants who made this work possible. Your contributions are vital for advancing our understanding of the disease and contribute to #ENDALZ.

biofinder_study avatar BioFINDER @biofinder_study ·
5 Aug 1952732797816209576

6⃣Do certain regions uniquely mediate a given tau-cognition association? - Yes, tau–immediate recall was mediated by several MTL regions, tau–recognition by hippocampus & tau–semantic fluency by inferior temporal gyrus.

More posts...